10 Stocks Kick Off Trading Week With Losses

Wall Street’s main indices began the shortened trading week on a lackluster note, albeit finishing in the green, as investors continued to digest corporate earnings results.

The S&P 500 led the charge, recording a modest 0.24 percent gain. However, the Dow Jones and the tech-heavy Nasdaq posted gains of only 0.02 percent and 0.07 percent, respectively.

Ten companies performed poorly on Tuesday amid a series of negative catalysts that disappointed investors. In this article, we identified the 10 worst performers and detailed the reasons behind their drop.

To come up with the list, we considered only the stocks with at least $2 billion in market capitalization and $5 million in daily trading volume.

A man in long sleeves looking at stock market data. Photo by Tima Miroshnichenko on Pexels

10. Baidu, Inc. (NASDAQ:BIDU)

Baidu, Inc. (NASDAQ:BIDU) retreated on Tuesday, losing 7.51 percent to close at $90.16 apiece as investors unloaded portfolios after the company’s third straight quarter of revenue drop.

In a statement on Tuesday, Baidu said revenues for the fourth quarter of 2024 dipped by 2.3 percent to RMB34.124 billion ($4.69 billion) from RMB34.951 billion ($4.8 billion) previously, while revenues for full-year 2024 dipped by 1 percent to RMB133 million from RMB134 million previously, amid cut-throat competition in the industry.

Net income for the quarter, however, doubled to RMB5.192 billion ($713 million) from RMB2.599 billion ($357 million) previously, while net income for the full year increased 17 percent to RMB23.76 billion ($3.26 billion) from RMB20.315 billion ($2.79 billion) year-on-year.

9. Tempus AI, Inc. (NASDAQ:TEM)

Shares of Tempus AI, Inc. (NASDAQ:TEM) declined by 8.37 percent on Tuesday to finish at $81.95 apiece as investors resorted to profit-taking following a four-day rally last week, buoyed by its partnership with a non-profit organization for the development of a treatment for follicular lymphoma.

In a statement, TEM said it partnered with the Institute for Follicular Lymphoma Innovation (IFLI) to develop targeted therapies for the disease by developing a real-world multimodal, deidentified data library in its data analytics platform, through which researchers may derive AI-driven insights to accelerate the development of follicular lymphoma treatments in an effort to improve patient outcomes.

The two parties will focus on prospectively generating multimodal data, particularly for POD24 patients who experience disease progression within 24 months of treatment.

Data from the National Cancer Institute as of 2024 showed that individuals with follicular lymphoma currently have a survival rate of 89.9 percent. It is most frequently diagnosed among people aged 65 to 74.